PARP1 and ovarian cancer: Because MCF7 MAGI1 KO cells showed defects in their DNA repair machinery, we tested whether olaparib, a PARP1 inhibitor used in patients to treat certain subtypes of breast and ovarian cancers, would render MCF7 MAGI1 KO cells more sensitive to cisplatin.